This study is in progress, not accepting new patients
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- To obtain contact information for a study center near you, click here.
- ID
- NCT01942135
- Phase
- Phase 3 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- At least 521 people participating
- Last Updated